Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.56 |
| ▸ | CTSS | P25774 | 4/20 | 0.53 |
| ▸ | CTSL | P07711 | 3/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 2/20 | 0.50 |
| ▸ | KYNU | Q16719 | 1/20 | 0.50 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29521267 | 1.00 | CTSK (0.56) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL2952201 | 1.00 | CTSK (0.56) | CTSKCTSSCTSLCTSBATM | |
| Hydrochloric Acid SCHEMBL29367832 | 0.99 | CTSK (0.55) | CTSKCTSSCTSLCTSBATM | |
| Hydrochloric Acid SCHEMBL28702723 | 0.99 | CTSK (0.55) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL16460327 | 0.88 | CTSK (0.63) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL16460328 | 0.88 | CTSK (0.63) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL3258258 | 0.87 | KYNU (0.63) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL4346138 | 0.87 | KYNU (0.63) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL2115471 | 0.87 | KYNU (0.63) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL30437751 | 0.87 | CTSK (0.56) | CTSKCTSSCTSLCTSBCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763621-B2 | Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS (FR) | 2010-07-27 | — | — | US | disclosed |
| US-7763621-B2 | Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS (FR) | 2010-07-27 | — | — | US | disclosed |
| US-7763621-B2 | Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS (FR) | 2010-07-27 | — | — | US | disclosed |
| US-7582640-B2 | Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS (FR) | 2009-09-01 | — | — | US | disclosed |
| US-7582640-B2 | Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS (FR) | 2009-09-01 | — | — | US | disclosed |
| US-7582640-B2 | Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS (FR) | 2009-09-01 | — | — | US | disclosed |
| US-20090149476-A1 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS | 2009-06-11 | — | — | US | disclosed |
| US-20090149476-A1 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS | 2009-06-11 | — | — | US | disclosed |
| US-20090149476-A1 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS | 2009-06-11 | — | — | US | disclosed |
| EP-1565467-B1 | NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | GALAPAGOS SAS (FR) | 2009-05-20 | — | — | EP | disclosed |
| US-20060052398-A1 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS NV (BE) | 2006-03-09 | — | — | US | disclosed |
| WO-2004048375-A1 | NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | PROSKELIA SAS (FR) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052398-A1 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | ADGRF1, C5AR2, ADGRE5 | CTSK 1391/4885CTSS 1246/4885CTSL 447/4885 |
| US-20090149476-A1 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | ADGRF1, C5AR2, ADGRE5 | CTSK 1391/4885CTSS 1246/4885CTSL 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.